EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism

Meng Liu iD, Junxin Xue, Changning Xue, Huibin Qi, Yuanzhi Tan, Xiaohan Wang, Shan Gao iD

Journal of Medicinal Chemistry · 09.07.2026 · 69 (13) · 15872-15887

DOI: 10.1021/acs.jmedchem.6c01013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.06.2026. Verfasst von Meng Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shandong Pediatric Drug Clinical Evaluation and R&D Research Center of Engineering Technology, The First Affiliated …. Hauptthemen laut MEDLINE: Benzimidazoles, fms-Like Tyrosine Kinase 3, Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Postdoctoral Innovation Project of Shandong Province, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzimidazolesfms-Like Tyrosine Kinase 3Histone Deacetylase InhibitorsLeukemia, Myeloid, AcuteDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsCell Line, TumorCell ProliferationMiceStructure-Activity RelationshipDrug SynergismPhenylurea CompoundsBenzothiazolesHistone Deacetylases

Substanzen

Benzimidazolesfms-Like Tyrosine Kinase 3Histone Deacetylase InhibitorsAntineoplastic AgentsFLT3 protein, humanPhenylurea CompoundsBenzothiazolesProtein Kinase Inhibitorsquizartinibbenzimidazole

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shandong Pediatric Drug Clinical Evaluation and R&D Research Center of Engineering Technology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial…
  • College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
  • Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.
  • Phase I Clinical Trail Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.

ORCID-Profile: Meng Liu, Shan Gao

Förderung

  • Postdoctoral Innovation Project of Shandong Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Liu, M., Xue, J., Xue, C., Qi, H., Tan, Y., Wang, X., & Gao, S. (2026). Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism. Journal of Medicinal Chemistry, 69(13), 15872-15887. https://doi.org/10.1021/acs.jmedchem.6c01013

Vancouver

Liu M, Xue J, Xue C, Qi H, Tan Y, Wang X, et al. Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism. Journal of Medicinal Chemistry. 2026;69(13):15872-15887. doi:10.1021/acs.jmedchem.6c01013

BibTeX
@article{Liu2026,
  author = {Liu, Meng and Xue, Junxin and Xue, Changning and Qi, Huibin and Tan, Yuanzhi and Wang, Xiaohan and Gao, Shan},
  title = {Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {13},
  pages = {15872--15887},
  doi = {10.1021/acs.jmedchem.6c01013}
}
Kostenlos starten →